Upfront Briefing
UCB agreed to acquire Neurona Therapeutics for $650M upfront plus up to $500M in milestones, for total consideration of up to $1.15B.
Novo Nordisk posted phase 3 HIBISCUS topline results for etavopivat in sickle cell disease, saying it met both co-primary endpoints while reducing vaso-occlusive crisis events and improving haemoglobin response.
And in weekend rumour tape, the Wall Street Journal reported Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2B, with a deal potentially reachable as soon as Monday.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,126.1 |
+1.2% |
+3.3% |
| Nasdaq 100 |
26,672.4 |
+1.3% |
+4.7% |
| Russell 2000 |
2,776.9 |
+2.1% |
+2.2% |
| Healthcare (XLV) |
148.8 |
+1.5% |
(3.9%) |
| Biotech (XBI) |
138.7 |
+2.4% |
+13.7% |
| Nasdaq Biotech (NBI) |
6,131.8 |
+1.6% |
+7.4% |
| Clinical Trials (BBC) |
47.4 |
+2.2% |
+22.6% |
|
- Beta led Friday’s move: the Russell 2000 (+2.1%) topped the tape and XBI (+2.4%) outperformed the S&P 500 (+1.2%), a sign that investors rotated back into higher-volatility growth after macro stress eased.
- The proximate driver was macro, not biotech-specific: Wall Street rallied as oil dropped sharply after the Strait of Hormuz reopening, easing inflation pressure and lifting risk appetite; that helped small-caps and biotech catch a stronger bid than defensive healthcare.
- The more interesting YTD split remains under the surface: XLV is still negative while XBI, NBI and especially BBC are materially positive, which says capital is still rewarding innovation beta over the broader healthcare complex; the drag on broader healthcare has come more from large-cap pharma and managed-care overhangs than from clinical-stage risk appetite.
- Market data: U.S. close Fri 17-Apr-2026.
The Big 3
|
1
|
UCB to buy Neurona in cell therapy deal worth up to $1.15B
|
- UCB agreed to acquire Neurona Therapeutics for $650M upfront plus up to $500M in milestones, for total consideration of up to $1.15B.
- Why it matters: UCB is paying a large upfront for NRTX-1001, a clinical-stage neuronal cell therapy being tested in phase 1/2 for drug-resistant mesial temporal lobe epilepsy, which makes this more than a thematic “cell therapy” headline: it is a hard strategic comp for advanced neuro cell-therapy assets. Just as important, UCB kept 2026 revenue guidance unchanged while saying the deal should still support high-single-digit to mid-teens adjusted EBITDA growth, suggesting the company views the asset as financially absorbable as well as strategically important.
- Source: Reuters
- More: BioPharma Dive; Endpoints; Fierce Biotech
|
|
2
|
Novo posts Phase 3 HIBISCUS topline results for etavopivat
|
- Novo Nordisk reported phase 3 HIBISCUS topline results for once-daily oral etavopivat in sickle cell disease, saying it met both co-primary endpoints; third-party coverage said the drug cut vaso-occlusive crises by 27% and delivered haemoglobin response in 48.7% of patients versus 7.2% on placebo.
- Why it matters: This reads through as a real late-stage de-risking event, not a soft “pipeline progress” headline. Etavopivat is a first-in-class oral PK activator, and a phase 3 win with both VOC and haemoglobin benefit gives Novo a differentiated rare-disease asset with a stated plan to file in 2H 2026. For investors, that matters because it adds a new commercial leg outside obesity while also creating a fresh comp set across sickle-cell programs trying to balance efficacy, convenience and chronic-use tolerability.
-
Source:
PR
- More: Reuters
|
|
3
|
Lilly said to be nearing a >$2B deal for in vivo CAR-T player Kelonia
|
-
The Wall Street Journal reported Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2B, with a deal potentially reachable as soon as Monday. Kelonia’s lead asset, KLN-1010, is an in vivo anti-BCMA CAR-T for relapsed/refractory multiple myeloma built on the company’s iGPS lentiviral platform.
-
Why it matters:
This reads less like a generic gene-delivery bet and more like a strategic move into in vivo CAR-T. Kelonia has positioned KLN-1010 around anti-BCMA activity without the usual ex vivo manufacturing burden, and the company reported 100% MRD-negative responses in the first four patients dosed at ASH 2025. For investors, the read-through is toward valuation support for in vivo CAR-T and cell-programming peers — and the proposed >$2B price tag is even more striking given the Journal said Kelonia has raised less than $60M and was last valued at roughly $100M in 2022.
-
Source:
Reuters
-
Watch: If talks hold, an announcement could come today.
|
Everything Else that broke
AACR is in full swing in San Diego (April 17–22), so a lot of this week's incremental read-through is clustering around meeting coverage, RAS data and policy mood music.
- AstraZeneca said tozorakimab delivered a statistically significant and clinically meaningful reduction in moderate-to-severe COPD exacerbations in the phase 3 MIRANDA study, adding to positive late-stage data from March. — Reuters
- Lilly’s Foundayo reached 1,390 patients in its first week, trailing Novo’s oral Wegovy launch; Lilly shares still rose roughly 2% on Friday, giving the product a small but visible link back into the day’s risk-on tape. — BioSpace
- AACR preview spotlights Revolution Medicines and a broader RAS theme. — Endpoints
- FDA is celebrating progress to end animal testing, but experts say there’s still a long way to go. — Fierce Biotech
- FDA’s budget proposal includes a policy wish list. — BioCentury
- At AACR, FDA veteran Pazdur warned of political influence and a “sense of anxiety.” — Fierce Biotech
- Monopar presented phase 3 data at AAN 2026 showing greater neurologic benefit with ALXN1840 versus standard of care in Wilson disease patients with neurologic symptoms. — PR
- KIMMTRAK reported a five-year survival update in first-line HLA-A*02:01+ metastatic uveal melanoma, saying it doubles the likelihood of being alive at five years. — PR
- argenx highlighted new AAN 2026 data supporting broader VYVGART use across MG and CIDP. — PR
- AACR coverage looked at KRAS drugmakers taking another, better swing at lung cancer as next-generation programs evolve. — Endpoints
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
UCB to buy Neurona for $650M upfront plus up to $500M in milestones, for total consideration of up to $1.15B. — Reuters
- Rumour: the Wall Street Journal reported Lilly is in advanced talks to acquire Kelonia Therapeutics for more than $2B, with a deal potentially reachable as soon as Monday; Kelonia’s lead, KLN-1010, is an in vivo anti-BCMA CAR-T for relapsed/refractory multiple myeloma. — Reuters
VC / Private Financings
- Pulnovo Medical announced an oversubscribed $100 million strategic financing round led by Medtronic, with continued support from EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed and Lilly Asia Ventures; new investor HSG also joined. — PR
IPOs / Follow-Ons
- Odyssey Therapeutics will try again to IPO, with Endpoints describing a warmer market backdrop for the attempt. — Endpoints
- BioCentury reported Kailera upsized its IPO, putting the obesity play among the year’s largest biotech flotations. — BioCentury
- Endpoints published an interview with Kailera’s CEO Renaud on the company’s IPO. — Endpoints
|
